STAT+: Emergent was aware of vaccine manufacturing issues even as it collected $27 million a month from U.S.
Under a contract awarded by the Trump administration, Emergent BioSolutions (EBS) was paid $27 million in monthly “reservation fees” to maintain its “readiness” to make Covid-19 vaccines, but the company was already aware of serious quality control problems at a Baltimore plant but failed to take any action, according to documents released by two House committees.
The manufacturing problems forced the company to destroy millions of doses of Johnson & Johnson (JNJ) Covid-19 vaccines earlier this year that were to have been made at the plant. In fact, a J&J audit conducted shortly after the contract was awarded found potential “weaknesses” and a “deficient” strategy for controlling contamination.
